# Postoperative Sugammadex After COVID-19

> **NCT05817019** · PHASE4 · UNKNOWN · sponsor: **Korea University Ansan Hospital** · enrollment: 300 (estimated)

## Conditions studied

- General Anesthesia
- COVID-19

## Interventions

- **DRUG:** Sugammadex Sodium
- **DRUG:** neostigmine 50µg/kg + glycopyrollate 0.01mg/kg

## Key facts

- **NCT ID:** NCT05817019
- **Lead sponsor:** Korea University Ansan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-20
- **Primary completion:** 2024-12-25
- **Final completion:** 2024-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817019, "Postoperative Sugammadex After COVID-19". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05817019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*